Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study.

Autor: Tye-Din JA; Immunology Division, The Walter and Eliza Hall Institute, Parkville, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia; Department of Gastroenterology, The Royal Melbourne Hospital, Parkville, VIC, Australia; Centre for Food & Allergy Research, Infection and Immunity, Murdoch Children's Research Institute, Parkville, VIC, Australia., Daveson AJM; Greater Brisbane Clinical School, Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia; Wesley Medical Research, Auchenflower, QLD, Australia; Coral Sea Clinical Research Institute, North Mackay, Queensland, Australia., Goel G; ImmusanT, Cambridge, Massachusetts, USA., Goldstein KE; ImmusanT, Cambridge, Massachusetts, USA., Hand HL; ImmusanT, Cambridge, Massachusetts, USA., Neff KM; ImmusanT, Cambridge, Massachusetts, USA., Popp A; University of Medicine and Pharmacy, Carol Davila, Bucharest, Romania; Department of Clinical Medicine, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Paediatrics, Tampere University Hospital, Tampere, Finland., Taavela J; Department of Clinical Medicine, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Paediatrics, Tampere University Hospital, Tampere, Finland., Maki M; Department of Clinical Medicine, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Paediatrics, Tampere University Hospital, Tampere, Finland., Isola J; Department of Clinical Medicine, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; Jilab, Tampere, Finland., Williams LJ; ImmusanT, Cambridge, Massachusetts, USA., Truitt KE; ImmusanT, Cambridge, Massachusetts, USA., Anderson RP; ImmusanT, Cambridge, Massachusetts, USA. Electronic address: robert.anderson2@health.qld.gov.au.

Publikováno v: The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2023 May; Vol. 8 (5), pp. 446-457. Date of Electronic Publication: 2023 Mar 07.

Masked bolus gluten challenge low in FODMAPs implicates nausea and vomiting as key symptoms associated with immune activation in treated coeliac disease.

Autor: Daveson AJM; Faculty of Medicine, University of Queensland, Brisbane, Qld, Australia., Tye-Din JA; Immunology Division, The Walter and Eliza Hall Institute, Parkville, Vic., Australia.; Department of Medical Biology, University of Melbourne, Parkville, Vic., Australia.; Department of Gastroenterology, The Royal Melbourne Hospital, Parkville, Vic., Australia.; Centre for Food & Allergy Research, Murdoch Children's Research Institute, Parkville, Vic., Australia., Goel G; ImmusanT, Inc., Cambridge, MA, USA., Goldstein KE; ImmusanT, Inc., Cambridge, MA, USA., Hand HL; ImmusanT, Inc., Cambridge, MA, USA., Neff KM; ImmusanT, Inc., Cambridge, MA, USA., Williams LJ; ImmusanT, Inc., Cambridge, MA, USA., Truitt KE; ImmusanT, Inc., Cambridge, MA, USA., Anderson RP; ImmusanT, Inc., Cambridge, MA, USA.

Publikováno v: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2020 Jan; Vol. 51 (2), pp. 244-252. Date of Electronic Publication: 2019 Nov 26.